Insulet (NASDAQ:PODD) Hits New 52-Week High - Time to Buy?

Key Points

• Insulet Corporation's stock reached a new 12-month high of $330.73, marking a significant increase from its previous close of $327.48.
• Analysts have raised their price targets for Insulet, with Canaccord Genuity setting a new target of $353.00 and Wells Fargo modifying theirs to $350.00, contributing to the company's strong buy ratings.
• Insulet reported a quarterly earnings per share of $1.17, exceeding estimates, and a revenue of $649.10 million, reflecting a year-over-year growth of 32.9%.

Insulet Corporation (NASDAQ:PODD - Get Free Report)'s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $330.23 and last traded at $330.73, with a volume of 19069 shares changing hands. The stock had previously closed at $327.48.

Analyst Ratings Changes

PODD has been the subject of a number of research reports. Raymond James Financial reissued an "outperform" rating and issued a $360.00 price objective (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Citigroup reissued a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. The Goldman Sachs Group initiated coverage on Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 price objective for the company. Canaccord Genuity Group raised their price objective on Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Finally, Barclays raised their price objective on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research note on Thursday. Sixteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $332.71.

Insulet Stock Up 0.9%

The stock has a fifty day moving average of $300.94 and a 200 day moving average of $285.91. The firm has a market capitalization of $23.28 billion, a P/E ratio of 100.54, a price-to-earnings-growth ratio of 2.77 and a beta of 1.35. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period last year, the company posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Institutional Trading of Insulet

A number of hedge funds have recently bought and sold shares of the business. State of Wyoming lifted its holdings in Insulet by 91.5% during the second quarter. State of Wyoming now owns 923 shares of the medical instruments supplier's stock worth $290,000 after acquiring an additional 441 shares during the period. CYBER HORNET ETFs LLC bought a new stake in shares of Insulet in the second quarter valued at $58,000. Castleark Management LLC bought a new stake in shares of Insulet in the second quarter valued at $14,977,000. FORA Capital LLC bought a new stake in shares of Insulet in the second quarter valued at $631,000. Finally, MUFG Securities EMEA plc bought a new stake in shares of Insulet in the second quarter valued at $65,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.